Hu An-bin, He Xiao-shun, Wu Zhi-peng, Zhu Xiao-feng, Ma Yi, Wang Dong-ping, Wang Guo-dong, Tai Qiang, Ju Wei-qiang, Wu Lin-wei, Huang Jie-fu
Organ Transplantation Center, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
Zhonghua Wai Ke Za Zhi. 2008 Aug 1;46(15):1126-8.
To evaluate efficacy and safety on steroid withdrawal at the seventh day after liver transplantation.
Seventy-six adult patients undergoing first cadaveric liver transplantation from October 2005 to October 2007 were randomly divided into 7 day (n = 40) and 3 month (n = 36) steroid withdrawal groups. All patients received FK506 3 mg and intravenous methylprednisolone 1000 mg during intra-operation and FK506 thereafter was adjusted to predefined 8 - 12 microg/L from day 1 to month 6. Patients in 7 day steroid withdrawal group received 500, 240, 200, 160, 80, 40 and 20 mg intravenous methylprednisolone tapered daily from postoperative day 1 to day 7. In 3 month steroid withdrawal group, patients received the same protocol as 7 day steroid withdrawal group for intravenous methylprednisolone tapered daily from postoperative day 1 to day 7 and thereafter received oral prednisone 48, 40, 32, 24, 16, 8, 4 mg tapered every 3 days and maintained 4 mg to the 3(rd) month. All patients were followed up for 6 months. The incidence of treated acute rejection and side effects were evaluated between two groups.
A total of 69 cases were fully followed up, and 7 cases were discontinued including death (n = 2), server infection (n = 2), protocol violation (n = 2) and retransplantation (n = 1). There were no statistical difference between 2 groups concerning the incidence of acute rejection, hypertension, hyperlipemia and other adverse events (P > 0.05), but significant difference in incidence of diabetes (17.5% vs. 38.9%, P = 0.047).
Steroid withdrawal strategy at day 7 is same safety and efficacy as steroid withdrawal at 3 month.
评估肝移植术后第7天停用类固醇的疗效和安全性。
将2005年10月至2007年10月接受首次尸体肝移植的76例成年患者随机分为7天(n = 40)和3个月(n = 36)类固醇撤药组。所有患者术中均接受FK506 3 mg和静脉注射甲泼尼龙1000 mg,术后第1天至第6个月将FK506调整至预定的8 - 12 μg/L。7天类固醇撤药组患者从术后第1天至第7天每天静脉注射甲泼尼龙,剂量依次为500、240、200、160、80、40和20 mg。在3个月类固醇撤药组中,患者从术后第1天至第7天接受与7天类固醇撤药组相同的静脉注射甲泼尼龙递减方案,此后每3天递减口服泼尼松剂量,依次为48、40、32、24、16、8、4 mg,并维持4 mg至第3个月。所有患者随访6个月。评估两组治疗急性排斥反应的发生率和副作用。
共69例患者完成随访,7例患者失访,包括死亡(n = 2)、严重感染(n = 2)、违反方案(n = 2)和再次移植(n = 1)。两组在急性排斥反应、高血压、高脂血症和其他不良事件的发生率方面无统计学差异(P > 0.05),但糖尿病发生率有显著差异(17.5%对38.9%,P = 0.047)。
术后第7天停用类固醇的策略与3个月停用类固醇的安全性和疗效相同。